Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engensis pain treatment checked for Long-Term safety

NCT ID NCT04055090

First seen Oct 31, 2025 · Last updated Jun 20, 2026 · Updated 37 times

Summary

This study followed 101 people who had previously received either the experimental drug Engensis or a placebo for painful diabetic neuropathy. No new treatment was given; researchers simply monitored participants for 6 months to see if any safety issues or lasting pain relief appeared. The goal was to understand whether Engensis remains safe and effective over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAINFUL DIABETIC NEUROPATHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Arizona Research Center

    Phoenix, Arizona, 85023, United States

  • Center for Clinical Research

    San Francisco, California, 94115, United States

  • Clinical Research of West Florida

    Tampa, Florida, 33603, United States

  • Clinical Trials, Inc.

    Little Rock, Arkansas, 72205, United States

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • EVMS (Eastern Virginia Medical School)

    Norfolk, Virginia, 23510, United States

  • Innovative Research of West Florida

    Clearwater, Florida, 33756, United States

  • Nerve and Muscle Center of Texas

    Houston, Texas, 77030, United States

  • Neurological Research Institute

    Santa Monica, California, 90404, United States

  • Northern California Research

    Sacramento, California, 95821, United States

  • Rainier Clinical Research Center, Inc.

    Renton, Washington, 98057, United States

  • Raleigh Neurology Associates, P.A.

    Raleigh, North Carolina, 27607, United States

  • The Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • University of Florida McKnight Brain Institute

    Gainesville, Florida, 32611, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Engensis (VM202)

What this could lead to

If successful, this could show that Engensis provides lasting pain relief for people with painful diabetic neuropathy.

What could go wrong

This is a follow-up study with no new treatment given, so it cannot prove effectiveness. Results depend on the original trial's outcomes, which may not be positive.

Conditions

The condition(s) this trial relates to.

diabetic neuropathy Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.